Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track RKTO with free AI briefings, catalyst countdowns, and dilution alerts.

RKTO · Rocket One Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.9M Cash on Hand

7.9mo Cash Runway

Follow RKTO by email Get an email when RKTO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RKTO, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Apr 2028 · Phase 2 · Recruiting · A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Registry primary completion date, not a results date
Sep 2028 · Phase 1 · Recruiting · A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhyth
Registry primary completion date, not a results date
Jun 2029 · Phase 1 · Recruiting · A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in
Registry primary completion date, not a results date
Dec 2029 · N/A · Recruiting · Danon Disease Natural History Study
Registry primary completion date, not a results date
Dec 2030 · N/A · Recruiting · PKP2-ACM Natural History Study
Registry primary completion date, not a results date
May 2026 · Phase 2 · Active Trial · Gene Therapy for Fanconi Anemia, Complementation Group A
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Xuebijing	Pulmonary Disease, Chronic Obstructive	Phase 4 · NCT02937974	Unknown
Mozafancogene Autotemcel	Fanconi Anemia Complementation Group A	Phase 2 · NCT04248439	Active not recruiting
RP-L201	Leukocyte Adhesion Defect - Type I	Phase 1/2 · NCT03812263	Completed
RP-L301	Pyruvate Kinase Deficiency	Phase 2 · NCT06422351	Suspended
Genetically Engineered Hematopoietic Ste	Fanconi Anemia	Phase 1 · NCT01331018	Terminated
Methylprednisolone	Fanconi Anemia	Phase 1 · NCT01331018	Terminated
RP-A501	Danon Disease	Phase 1 · NCT03882437	Unknown
Autologous CD34+-enriched HSPCs Transduc	Infantile Malignant Osteopetrosis	Phase 1 · NCT04525352	Terminated

Also used in these trials (approved or third-party drugs, not RKTO's own candidates): Filgrastim, Plerixafor, Prednisone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RKTO holds $7.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations, an estimated runway of 7.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Cash runway 8 months +30
Share count +88% in a year +20

Recent financing filings on SEC EDGAR:

Apr 2, 2026 · Private placement (8-K Item 3.02) · 8-K
Mar 28, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RKTO files for a raise →

Get the full RKTO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RKTO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z